Letetresgene autoleucel (lete-cel) showed a 42% response rate in a phase 2 trial for synovial sarcoma and myxoid/round cell liposarcoma. The trial included 64 patients, with 41% response in synovial ...
Preclinical data confirmed ACR-368 as potentially therapeutic in DSRCT, and 19 patients were enrolled in a subsequent clinical trial. Treatment was well tolerated, and cytopenias were managed using ...
Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials In this pilot study, we assessed the ...
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra, also known as afami-cel) for the treatment of adults with a rare ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
“By dividing and conquering…we’re seeing responses in multiple different subtypes of sarcoma…and moving toward more of an individualized therapy that we try to design for every patient, where we take ...
The phase 1/2 SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced soft tissue sarcoma. The study investigators from City of Hope ...
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor ...
Afamitresgene-autoleucel is an autologous T-cell immunotherapy designed to target cancer cells in solid tumors expressing melanoma-associated antigen A4. The Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results